INTRODUCTION

Sleeping Beauty transposon system for nonviral engineering of CAR-T cells
The Sleeping Beauty (SB) transposon system [1] has been developed as a useful and promising tool for genetic engineering, including gene therapies (recently reviewed in [27] ).
The major advantage of SB gene delivery is that it combines the favorable features of viral vectors with those of naked DNA molecules, namely i) permanent insertion of transgene constructs into the genome by the transposition mechanism leads to sustained (potentially life-long) and efficient transgene expression in preclinical animal models (recently reviewed in [4] [5] [6] ); ii) transposon vectors can be maintained and propagated as plasmid DNA, which makes vector manufacture scalable and cost-effective, and only requires S1 biological safety conditions, thereby significantly simplifying manufacture of the cell-based product. In addition, transposons can deliver larger genetic cargoes than viruses [8] , and transposonbased vectors have an attractive safety profile [9] [10] [11] [12] [13] .
One exciting area of therapeutic cell engineering with immediate translational relevance is adoptive immunotherapy with tumor-reactive T cells that are engineered by gene transfer to express a synthetic chimeric antigen receptor (CAR) [14, 15] , resulting in selective tumor cell killing. The most advanced clinical development is the use of CARs specific for the B-lineage marker CD19. Several study groups have demonstrated that CD19 CAR-T cells are able to induce durable complete remissions in patients with chemotherapyand radiotherapy-refractory B-cell acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [16] [17] [18] [19] [20] [21] [22] [23] . Two CAR-T cell products have obtained marketing authorization for the treatment of certain CD19-positive ALL and NHL.
SB has recently made a successful clinical debut in two studies of CD19 CAR-T cell therapy [24] . These studies showed that the administration of SB-engineered CD19specific CAR-T cells is safe, and augments the Graft-versus-Leukemia effect in patients who had undergone prior hematopoietic stem cell transplantation. We have recently shown that CD19 CAR-T cells engineered by SB transposition and lentiviral transduction are equally effective in pre-clinical lymphoma models in vitro and in vivo [25] , and that vectorization of the SB100X hyperactive transposase and a CAR transposon as minicircle (MC) DNA reduces toxicity and significantly improves transposition efficacy [25] . As a consequence, therapeutic doses of CD19 CAR-T cells can be obtained within as short as 14 days from 1 x 10 6 input T cells with our MC-based SB approach, and the manufacturing process can be shortened to 72 hours or less, if higher input T cell numbers are utilized.
Another clinical proof-of-concept for CAR-T cell therapy has been obtained in multiple myeloma, a hematologic malignancy with clonal proliferation of plasma cells. The lead antigen for CAR-T cells in multiple myeloma is B cell maturation antigen (BCMA). A recent clinical trial with BCMA-specific CAR-T cells has highlighted their therapeutic potential with several partial and complete remissions [26] . However, downregulation of antigen expression and, as a consequence, the emergence of myeloma cell variants with antigen loss have been described [26] , underscoring the need to identify and validate additional target antigens. We have recently shown that CAR-T cells targeting the alternative myeloma antigen SLAMF7 are effective in pre-clinical models [27] . We are preparing a multi-center clinical trial with SLAMF7-specific CAR-T cells engineered with SB gene transfer (http://www.caramba-cart.eu/).
RESULTS
Assessment of residual transposase as a safety parameter of a Sleeping Beautyengineered SLAMF7 CAR-T cell product
We applied a previously established protocol for ex vivo engineering of human T cells with SB vectors [25] , albeit modified for GMP-compatibility and scaled to clinical production, stably delivering the SLAMF7 CAR by an electroporation procedure. In this procedure, SB100X transposase is encoded by mRNA and the SLAMF7 CAR transposon as MC. We generated three independent lots of SLAMF7 CAR-T cells from PBMCs of three independent healthy donor volunteers.
Stability of genomically integrated transgenes is of paramount importance for clinical applications. That is, ideally, transposition should take place only once during transfer of the therapeutic transgene from the transfected vectors into the cellular genome. Any further transposition event between chromosomal locations is undesired. One major determinant of potentially on-going transposition events in cell populations is the prolonged availability of the transposase. In this context, supplying the SB transposase in the form of mRNA has the added advantage of clearance of both the mRNA and the encoded transposase protein in the 14-day expansion period of CAR-T cell manufacturing. Importantly, the half-life of SB transposase has been estimated to be ~80 h in cycloheximide-treated cultured cells [28] .
In order to address the potential presence of the SB100X transposase at the end of the manufacturing period, cell populations from three independent validation runs were collected, and protein extracts analyzed by Western blotting alongside known amounts of recombinant purified SB100X transposase (Fig. 1) . The detection limit of SB100X through chemiluminescent Western blotting in this procedure was 50 pg ( Fig. 1) , which corresponds to ~7.66 x 10 8 SB100X transposase molecules (SB100X = ~39.29 kDa). Because we did not observe a band corresponding to the SB100X transposase in the SLAMF7 CAR-T cell extracts ( Fig. 1) , we conclude that the detection limit of this procedure is ~766 SB100X molecules per cell, and all three validation runs contain residual SB transposase below this limit. Furthermore, taking into account the half-life of SB transposase protein [28] and the length of the culture process, we consider the SLAMF7 CAR-T cell product to be negative for residual transposase. 6
Vector copy number of genomically integrated SLAMF7 CAR transposons
With any vector that integrates into chromosomes in a semi-random manner comes the potential risk of insertional mutagenesis leading to transcriptional activation or inactivation of cellular genes [29] . Such genotoxic effects can have devastating consequences for the cell and the whole organism, including the development of cancer. We consider at least two factors that contribute to the potential genotoxicity of an integrating vector system: vector copy number per genome and genome-wide integration profile.
We first determined the numbers of SB transposon integrations obtained per T cell genome. Quantitative droplet digital PCR (ddPCR) was performed using unselected bulk cell populations of SLAMF7 CAR-T cells harvested 14 days post-nucleofection. The average vector copy number (VCN) per diploid genome in the three validation runs was 8, 6 and 12 ( Fig. 2) , which falls within the range of VCNs typically seen with CAR-T cells manufactured with viral gene transfer systems. We nevertheless note that VCNs can potentially be decreased by applying limited amounts of transposon and transposase components [30, 31] at the electroporation step. 
Random insertion profile of the SLAMF7 CAR Sleeping Beauty vectors in the T cell genome
SB displays considerable specificity in target site selection at the primary DNA sequence level in that TA dinucleotides are near-obligate target sites [32] . We have previously undertaken a comparative study addressing target site selection properties of the SB and piggyBac (PB) transposons as well as MLV-derived gammaretroviral and HIV-derived lentiviral systems in primary human CD4 + T cells [33] . Our bioinformatic analyses included mapping against the T cell genome with respect to proximity to genes, transcriptional start sites (TSSs), CpG islands, DNaseI hypersensitive sites, chromatin marks and transcriptional status of genes. The SB transposon displayed the least deviation from random with respect to genome-wide distribution: no apparent bias was seen for either heterochromatin marks or euchromatin marks and only a weak correlation with transcriptional status of targeted genes was detected [33] . Our analyses collectively established a favorable integration profile of the SB transposon, suggesting that SB might be safer for therapeutic gene delivery than the integrating viral vectors that are currently used in clinical trials.
We constructed insertion site libraries from polyclonal SLAMF7 CAR-T cells for massive parallel sequencing on the Illumina MiSeq platform. We mapped and characterized from the three independent samples 5738, 6349 and 18574 unique insertion sites of the SLAMF7 CAR transposon. We detected the characteristic palindromic ATATATAT motif, which contains the TA dinucleotide target sequence of SB adjacent to all our MC-derived transposons ( Fig. 3) , similarly to what has been found for SB transposons mobilized from conventional donor plasmids [33, 34] . We then analyzed whether there was a preference of SLAMF7 CAR transposon insertions into distinct sites of the genome, e.g. exons and introns, genes and cancerrelated genes. We found that transpositions had occurred with only a modest, yet statistically significant (p<0.001) bias towards genic categories (Fig. 4) ; however, in all evaluated categories this preference was substantially smaller than previously found for lentiviral and gammaretroviral integrations [25, 33] . Importantly, transposon insertions showed only a ~1.2fold enrichment in genes and a ~1.4-fold enrichment in cancer-related genes relative to the expected random frequency. Concordantly, CAR transposons were also inserted into nongenic regions in a close-to-random manner (~0.9-fold compared to random) ( Fig. 4) .
Figure 4. Genome-wide distribution of SLAMF7 CAR-containing SB transposons in the T cell genome. Distribution of SB insertions in functional genomic segments of human T cells. Numbers
show relative enrichment above the random frequency (set to 1). Color intensities depict the degree of deviation from the expected random distribution (red: overrepresentation; blue: underrepresentation). downTES10kb stands for genomic regions extending 10 kb downstream from the transcriptional end sites of genes. upTSS10kb indicate 10-kb-long genomic segments upstream of transcriptional start sites of genes.
DISCUSSION
Here we manufactured SLAMF7 CAR-T cells with a robust ex vivo protocol of virus-free gene delivery using the SB transposon system, and characterized these CAR-T cells with respect to three parameters that are important for the assessment of safety aspects associated with the engineered cell product: the presence of residual transposase at the end of the manufacturing cycle, the number of vector copies per target cell genome and genome-wide insertion profile of the integrated transgenes. Our results overall support the applicability of these cells for human therapy. First, we have not detected residual SB transposase in the CAR-T cells at day 14 post-electroporation. Because human cells do not express SB transposase endogenously, this finding suggests that transposition is confined to an initial time window after electroporation when transposition can occur from the transfected MCs into the T cell genome. At later timepoints, further rounds of transposition are inhibited in the absence of transposase, which is key to maintenance of genomic stability of the cell product. Second, average vector copy numbers of integrated SLAMF7 CAR transgenes per T cell genome fall within the range that is considered safe in the context of human T lymphocytes. Importantly, vector-driven insertional oncogenesis has not been observed to date in retroviral-and lentiviral-transduced terminally differentiated T cells [35] .
Finally, random genomic distribution and lack of a pronounced preference for integration into genes (including oncogenes and tumor suppressors) further enhances the safety profile of SB gene delivery.
The advantages of using the SB system for gene therapy include the ease and reduced cost of manufacturing of clinical-grade, plasmid-based vectors compared to recombinant viral vectors [36] , scalability of vector production, the ease of ensuring quality control for clinical use, and indefinite storage with absolute fidelity. In addition, there is pronounced flexibility with respect to a wide range of human cell types that are amenable to SB transposon-based nonviral gene delivery and with respect to a wide variety of transgene cassettes that can be efficiently incorporated into the target cell genome by this system.
Indeed, it has recently been shown that allogeneic cytokine-induced killer (CIK) cells support highly efficient SB gene delivery, allowing the generation of CD19 CAR-CIK cells for clinical application in ALL patients [37] . In the context of adoptive T cell therapies, therapeutic T cell receptors (TCRs) can be efficiently introduced into T cell populations, and it was recently shown that the MC technology can boost TCR gene transfer with SB transposon vectors while reducing cellular toxicities [38] . Therefore, we consider SB transposition as a key enabling technology in order to make CAR-T cell therapy available on a global scale and in large patient cohorts.
MATERIALS and METHODS
Transposon vector components. The major functional components of MC-based transposon vectors have been previously described [25] . For the current work, the CD19specific CAR was replaced by a SLAMF7-specific CAR fused with a T2A element and truncated epidermal growth factor receptor (EGFRt) [27] . A MC transposon vector encoding SLAMF7 CAR_EGFRt transposon was generated from the parental pT2-based plasmid by PlasmidFactory (Bielefeld) using site-specific recombination and purified by affinity chromatography. SB100X mRNA was produced by in vitro transcription by BioNTech (Idar-Oberstein). Vector copy number analysis. The procedure described in [31] was followed. 200 ng of genomic DNA (gDNA) was digested with 20-20 units of DpnI and MluCI restriction enzymes (NEB) in 30 µl final reaction volume overnight in order to eliminate nonintegrated transposon MC DNA present in the samples and to fragment the gDNA, respectively. The samples were subjected to PCR amplifications using Taqman probes and primers specific for the transgene cargo of the transposon embracing three DpnI recognition sites. Another set of primers and a Taqman probe specific for the single-copy human RPP30 gene to measure genome copy number of the pooled T cells. Triplicate PCR reactions were performed in 20 µl final volume with 10 ng of fragmented gDNA using the ddPCR Supermix for Probes (No dUTP) master mix (Biorad) with 11-11 pmol primers and 50-50 pmol of TaqMan probes (for sequences of primers and probes see 
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